Cargando…

Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV

INTRODUCTION: This review summarizes the current dosing recommendations for antiretroviral (ARV) drugs in the international pediatric guidelines of the World Health Organization (WHO), US Department of Health and Human Services (DHHS), and Pediatric European Network for Treatment of AIDS (PENTA), an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waalewijn, Hylke, Turkova, Anna, Rakhmanina, Natella, Cressey, Tim R., Penazzato, Martina, Colbers, Angela, Burger, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Therapeutic Drug Monitoring 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636807/ https://www.ncbi.nlm.nih.gov/pubmed/31008997 http://dx.doi.org/10.1097/FTD.0000000000000637

Ejemplares similares

The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV
por: Rojo, Pablo, et al.
Publicado: (2020)

Antiretroviral therapy interruptions: impact on HIV treatment and transmission
por: Dubrocq, Gueorgui, et al.
Publicado: (2018)

Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
por: Bukkems, Vera E., et al.
Publicado: (2020)

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
por: Jacobs, Tom G, et al.
Publicado: (2020)

Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus
por: Colbers, Angela, et al.
Publicado: (2019)

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents
por: Chandasana, Hardik, et al.
Publicado: (2023)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy
por: Dubrocq, Gueorgui, et al.
Publicado: (2017)

HIV Drug Resistance in Children and Adolescents: Always a Challenge?
por: Koay, Wei Li A., et al.
Publicado: (2021)

Clinical outcomes among adolescents living with HIV in Kenya following initiation on antiretroviral treatment
por: Kose, Judith, et al.
Publicado: (2022)

Outcomes of modern antiretroviral therapy in obese individuals living with HIV
por: Zino, L, et al.
Publicado: (2022)

Predictive Models for Maximum Recommended Therapeutic Dose of Antiretroviral Drugs
por: Branham, Michael Lee, et al.
Publicado: (2012)

Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV
por: Ford, Deborah, et al.
Publicado: (2018)

Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV
por: Zino, Leena, et al.
Publicado: (2022)

Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV
por: Eke, Ahizechukwu C., et al.
Publicado: (2020)

Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA
por: Rakhmanina, Natella, et al.
Publicado: (2016)

Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations
por: Doherty, Kathleen, et al.
Publicado: (2014)

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
por: Waalewijn, Hylke, et al.
Publicado: (2022)

Pilot evaluation of an enzymatic assay for rapid measurement of antiretroviral drug concentrations
por: Olanrewaju, Ayokunle O., et al.
Publicado: (2021)

Are we there yet? 40 years of successes and challenges for children and adolescents living with HIV
por: Vreeman, Rachel C, et al.
Publicado: (2021)

Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV
por: Foster, C, et al.
Publicado: (2016)

User-Centered Development of an Online Platform for Drug Dosing Recommendations in Pediatrics
por: Rödle, Wolfgang, et al.
Publicado: (2019)

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
por: Turkova, Anna, et al.
Publicado: (2022)

Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa
por: Waalewijn, Hylke, et al.
Publicado: (2022)

Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots
por: Meesters, Roland J. W., et al.
Publicado: (2010)

Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations
por: Monge, Susana, et al.
Publicado: (2014)

Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients
por: Jia, Mengmeng, et al.
Publicado: (2022)

Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to action
por: Penazzato, Martina, et al.
Publicado: (2022)

Optimizing drugs to reach treatment targets for children and adolescents living with HIV
por: Penazzato, Martina, et al.
Publicado: (2015)

Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial
por: Bevers, Lisanne A H, et al.
Publicado: (2023)

Mechanistic Modeling of Placental Drug Transfer in Humans: How Do Differences in Maternal/Fetal Fraction of Unbound Drug and Placental Influx/Efflux Transfer Rates Affect Fetal Pharmacokinetics?
por: Liu, Xiaomei I., et al.
Publicado: (2021)

Prevalence of Drug–Drug Interactions with Hormonal Contraceptives and Antiretrovirals in Women Living with HIV
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Too bad! Fixed dose combination antiretroviral drugs
por: Agyarko-Poku, Thomas, et al.
Publicado: (2014)

Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV
por: Jacobs, Tom G, et al.
Publicado: (2021)

Concomitant Intake of Coca‐Cola to Manage the Drug–Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers
por: van Seyen, Minou, et al.
Publicado: (2019)

Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs
por: Livio, Françoise, et al.
Publicado: (2019)

Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings
por: Paengsai, Ninutcha, et al.
Publicado: (2019)

Hemorrhagic Stroke in an Adolescent Female with HIV-Associated Thrombotic Thrombocytopenic Purpura
por: Rakhmanina, Natella, et al.
Publicado: (2014)

A randomized study of intensified antiretroviral treatment monitoring versus standard-of-care for prevention of drug resistance and antiretroviral treatment switch
por: Hermans, Lucas E., et al.
Publicado: (2022)

Potential risk of drug–drug interactions with hormonal contraceptives and antiretrovirals: prevalence in women living with HIV
por: Murray, Milena M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_233euuo1i39g4qtaa4i9dluhaj